Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renaissance: Reversing Immunotherapy Resistance in mTNBC
NCT05076682Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of choline, sodium cromoglycate, efavirenz, trastuzumab rezetecan, SHR-A2102 in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Jun 2022; status: recruiting.
02
Drugs
cholinesodium cromoglycateefavirenztrastuzumab rezetecanSHR-A2102
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05076682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076682.